#China #Hangzhou #WuXi Biologics #EffiX™ #recombinant proteins

WuXi Biologics Launches EffiX™ Microbial Expression Platform

WuXi Biologics, known as a prominent global Contract Research, Development, and Manufacturing Organization (CRDMO), recently revealed its innovative EffiX™ platform. This new technology aims to address the increasing industry demand for efficient production systems in the biopharmaceutical sector.

The EffiX™ platform is designed to provide a high-yield, stable expression system based on the non-lysogenic E. coli, a significant advancement for those developing and manufacturing non-monoclonal antibody recombinant proteins and plasmid DNA on a global scale. By achieving titers exceeding 15 g/L for non-mAb proteins and over 1 g/L for plasmid DNA, EffiX™ stands out as a comprehensive solution capable of catering to diverse production needs.

The growing market for microbial-derived products is fueled by the increasing demand for complex biomolecules, including antibody fragments, nanobodies, enzymes, and various antigens. WuXi Biologics is positioning the EffiX™ platform at the forefront of biomanufacturing, providing the industry with robust solutions for next-generation therapies.

In addition to its high-yield capabilities, the EffiX™ platform streamlines production processes to accommodate custom project requirements, enhancing overall throughput from initial research stages to large-scale commercial manufacturing. This integration provides WuXi’s global partners with an efficient and cost-effective Chemistry, Manufacturing, and Controls (CMC) strategy.

Dr. Chris Chen, CEO of WuXi Biologics, expressed enthusiasm over the introduction of the EffiX™ platform, highlighting its potential impact on product quality, scalability, and developmental flexibility. He emphasized that this launch reflects WuXi Biologics' commitment to innovation in supporting global partners in delivering high-quality and affordable biologics to patients worldwide.

As part of a larger strategy to innovate, the EffiX™ platform integrates into WuXi Biologics’ broader technology portfolio, focusing primarily on microbial expression systems. This extensive platform not only covers early-stage research but also extends to CMC development and GMP manufacturing, thereby promising rapid, cost-effective solutions for various therapeutic modalities.

WuXi Biologics (stock code: 2269.HK) is a pioneer in end-to-end solutions for biologics development, dedicated to improving health outcomes for patients through the effective and efficient advancement of drug manufacturing.

With a global team of over 12,000 experts across multiple countries, including China, the United States, Ireland, Germany, and Singapore, WuXi Biologics excels in providing comprehensive solutions that optimize the journey from biological concepts to commercial products. Their ongoing support of 817 client projects signifies their robust presence and expertise in the biologics market, ensuring that they continue to lead the charge in producing effective therapies.

Furthermore, WuXi Biologics actively embraces its Environmental, Social, and Governance (ESG) responsibilities as part of its core strategy. With advanced biomanufacturing technologies that prioritize clean energy, WuXi is on a mission to set standards in sustainability within the biologics CRDMO sector. An established ESG committee, spearheaded by their CEO, underscores their commitment to implementing comprehensive sustainable practices.

For more information on WuXi Biologics and their innovative solutions, please visit www.wuxibiologics.com.